Oral

[O2-5] Hepadnavirus2

Mon. Nov 14, 2022 1:50 PM - 3:20 PM Room 5 (Conference Room 109)

Chair:Tomoyuki Honda(Department of Virology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University), Ryosuke Suzuki(National Institute of Infectious Diseases)

+Add all to schedule

1:50 PM - 2:05 PM

[O2-5-1] A covalent SRPK1/2 inhibitor, SRPKIN-1, inhibits virion formation and de-capsidation of HBV

*Kenji Nakashima¹, Xiaofang Li¹, Masahiko Ito¹, Tetsuro Suzuki¹ (1. Hamamatsu University School of Medicine)

2:05 PM - 2:20 PM

[O2-5-2] Oxidative stress sensor Keap1 recognizes HBx protein to activate the Nrf2/ARE signaling pathway, thereby inhibiting hepatitis B virus replication.

*Adi Ariffianto¹, Lin Deng¹, Chieko Matsui¹, Takayuki Abe¹, Masahiko Ito², Tetsuro Suzuki², Yoshiharu Matsuuura³, Ikuo Shoji¹ (1. Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan, 2. Department of Virology and Parasitology, Hamamatsu University School of Medicine, Hamamatsu, Japan, 3. Center for Infectious Diseases Education and Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan)

2:20 PM - 2:35 PM

[O2-5-3] Identification of antiviral agents targeting HBV Enhancer I-X promoter and their mechanisms of action

*Atsuya Yamashita¹, Hirotake Kasai¹, Tomohisa Tanaka¹, Naoki Ohtsu¹, Yasunori Akaike¹, Kohji Moriishi^1,2 (1. University of Yamanashi, 2. Hokkaido University)

2:35 PM - 2:50 PM

[O2-5-4] A novel bile acid derivative inhibits HBV infection via sodium taurocholate co-transporting polypeptide

*GN Rsi Suwardana¹, Takayuki Abe¹, Kuroki Daisuke¹, Lin Deng¹, Chieko Matsui¹, Masafumi Ueda², Takahashi Okitsu³, Manabu Hatano³, Kunitada Shimotohno⁴, Ikuo Shoji¹ (1. Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan, 2. Medicinal Chemistry Laboratory, Kobe Pharmaceutical University, Kobe, Japan, 3. Laboratory of Organic Chemistry for Life Science, Kobe Pharmaceutical University, Kobe, Japan, 4. National Center for Global Health and Medicine, Chiba, Japan)

2:50 PM - 3:05 PM

[O2-5-5] Hepatic parenchymal cell-tropic innate immune modulator using poly(I:C) reduced HBV cccDNA in vivo

*Naoki Yamamoto¹, Yusuke Sato², Shuko Murakami³, Yasuhito Tanaka⁴, Hideyoshi Harashima², Michinori Kohara¹ (1. Tokyo Metropolitan Institute of Medical Science, 2. Hokkaido University, 3. Nagoya City University Graduate School of Medical Sciences, 4. Kumamoto University)

3:05 PM - 3:20 PM

[O2-5-6] Construction of an animal model transplanted with HBV-producing cells for hepatitis B drug discovery

*GUANG YANG¹, YUTAKA FURUTANI², HARUYO AOYAGI¹, RYUDA UEDA¹, MADOKA SONOBE¹, KENJI OGAWA³, TAKASHI NIWA^4,5, KAORU KOBAYASHI⁶, TAKAMITU HOSOYA^4,5, YOUSUKE KANAYAMA^4,8, YASUYOSHI WATANABE⁴, SUMIKO NAGOSHI⁷, TOMOKAZU MATSUURA², TAKAJI WAKITA¹, MASAMICHI MURAMATSU¹, KOUICHI WATASHI¹, KOUSHO WAKAE¹, HIDEKI AIZAKI¹ (1. National Institute of Infectious Diseases, 2. The Jikei University School of Medicine, 3. Nihon University, 4. Institute of Physical and Chemical Research, 5. Tokyo Medical and Dental University, 6. Meiji Pharmaceutical University, 7. Saitama Medical University, 8. Kavli IPMU, The University of Tokyo)

Session information